MOTS-c

What is MOTS-c? Effects of the mitochondrial peptide

MOTS-c is a peptide your body makes from 16 amino acids. As a mitochondrial peptide, it is encoded directly in the DNA of your cells' power plants. In research, MOTS-c is often called an 'exercise mimetic' because it switches on metabolic processes that intense exercise would normally trigger. It is currently not approved as a drug for humans by agencies such as the FDA.

Your body produces MOTS-c naturally, and levels rise after physical exertion. A study of 40 overweight children and adolescents showed that circulating MOTS-c levels were only reduced in boys and were directly linked to insulin resistance. The peptide was first described in detail by the USC in 2015. Since then, it has been intensively researched, with the focus so far largely on animal studies.

Use and dosage forms of MOTS-c

In scientific studies and in gray market practice, MOTS-c is injected subcutaneously, usually into the fat tissue of the abdomen or thigh. A human pilot study from 2025 examined the administration of 10 mg per week over a period of 12 weeks [PMID 39428157]. The current phase 2a study MOTS-MET (NCT07505745) also uses subcutaneous injection over 12 weeks, although the exact dosage is not yet publicly known.

On the gray market, vials with 10, 20, and 40 mg are available as lyophilized powder. Unsubstantiated user reports frequently mention dosages of 5-10 mg per week, often in cycles of 8-12 weeks followed by a break of 4-8 weeks. These practices are based on community experience and not on clinically tested protocols.

Although oral forms are offered, there is no scientific basis for them. The bioavailability of oral MOTS-c is considered very low due to its peptide structure, and precise data on absorption into the blood are lacking.

From vial to use: Reconstitution and calculation

MOTS-c is supplied as a freeze-dried powder and must be dissolved with sterile water. Since there is no official approval, there is no standardized protocol. The following example calculation serves for documentation purposes and does not constitute a medical instruction.

Example calculation: 10 mg vial, 5 mg per injection

At a concentration of 5 mg/ml, 1.0 ml corresponds to exactly 5 mg of MOTS-c. For the 10 mg dose used in the pilot study, 2 ml would need to be injected with this mixture. Alternatively, a 10 mg vial can be dissolved with only 1 ml of BAC water to achieve a concentration of 10 mg/ml. The amount of water thus determines the injection volume.

Sterile technique is essential when mixing. The water should flow slowly along the glass wall to dissolve the powder gently. Gentle swirling replaces shaking. You can find a detailed step-by-step guide to reconstitution on our page. Note that there is no guarantee of purity for gray market products; information on protection when ordering peptides is therefore important.

Mechanism of action: AMPK activation and metabolism

MOTS-c intervenes in the folate-purine cycle and causes the cell to switch its energy metabolism. This activates the energy sensor AMPK - a mechanism also used by the diabetes drug metformin. This leads to increased glucose uptake and increased fat burning in the cell.

Because of this performance-enhancing effect, MOTS-c has been on the WADA prohibited list since 2024 (category S4.4, AMPK activators). Its use is prohibited at all times for competitive athletes. The US Anti-Doping Agency USADA warns against MOTS-c because it is an experimental peptide without therapeutic approval.

Effectiveness of MOTS-c in studies

In animal experiments, mice given MOTS-c showed improved insulin sensitivity and less weight gain on a high-fat diet. Preclinical data from 2025 suggest that mitochondrial respiration can improve in the diabetic heart [PMID 40661667] and that pancreatic beta cells are protected from aging processes [PMID 40855115].

In humans, MOTS-c levels naturally decline with age. Low levels are associated with type 2 diabetes, gestational diabetes, and coronary endothelial dysfunction. The first clinical intervention study in humans was published in 2025.

The MOTS-MET study program and the human pilot study

Human pilot study 2025 (PMID 39428157)

This study, published in the Journal of Clinical Endocrinology & Metabolism, examined 24 people with insulin resistance. Over 12 weeks, they received 10 mg of MOTS-c subcutaneously each week. The results showed:

• HOMA-IR (insulin resistance marker) decreased from 3.1 to 2.3 (p=0.041).
• 2-hour blood glucose in the glucose tolerance test decreased by 12 ± 4 mg/dL.
• The treatment was well tolerated, with no serious side effects.

Since this is a pilot study without a control group, these data should be considered preliminary and must be confirmed in larger studies.

MOTS-MET Phase 2a (NCT07505745)

The phase 2a study MOTS-MET (sponsor: Hudson Biotech) has been recruiting participants since February 2026. This randomized, placebo-controlled, double-blind study is examining whether MOTS-c improves insulin sensitivity in prediabetes and overweight. Participants receive lifestyle counseling in addition to the medication and are monitored for 16 weeks. Initial results are expected in 2027/2028.

CB4211 (CohBar) - development discontinued

The analog CB4211 was tested in a phase 1 study in patients with fatty liver disease (NAFLD). It lowered liver fat markers such as ALT by -21% and AST by -28%. Despite the safety signals, development of CB4211 was discontinued; it is no longer being pursued as a drug candidate.

Dosage: Insights from research and practice

There are no official medical dosage recommendations. The following table summarizes the protocols used in research and on the gray market:

Animal doses cannot be directly transferred to humans. A linear conversion for a 70 kg person would lead to unrealistically high amounts. The human study therefore used a fixed dose of 10 mg per week.

Handling & storage of MOTS-c

Since MOTS-c is not approved as a drug, storage recommendations are based on general peptide practice:

• Undissolved powder: Store at -20 °C or in the refrigerator at 2-8 °C.
• After reconstitution with BAC water: Store in the refrigerator at 2-8 °C and use within 30 days.
• Avoid shaking; gentle swirling is sufficient for dissolution.
• Protect the vial from direct light and heat.

You can find more details in our guides on storage. The quality of gray market products is not subject to pharmaceutical control.

Side effects and risks

The data on the safety of externally administered MOTS-c in humans is limited [1, 2, 3, 4, 6, 7]. The pilot study with n=24 participants provided initial indications of good tolerability, but it is too small to capture rare side effects [PMID 39428157].

Possible risks include local reactions at the injection site as well as unknown long-term effects on metabolism or the immune system. In cardiovascular disease, there is a theoretical risk due to the metabolic effects.

Common application errors:

• Wrong concentration due to inaccurate measuring of the water amount.
• Lack of hygiene when injecting, which can lead to infections.
• Dangerous overdose due to incorrect conversion of animal doses.
• Missing breaks, which could theoretically lead to AMPK desensitization.

Legal status: WADA list and FDA approval

MOTS-c is not FDA-approved and has no approval as a drug in any Western country. There are no officially verified data on safety in routine use. It is obtained through the gray market without quality control.

Athletes must note: Since 2024, WADA has listed MOTS-c as a prohibited substance (category S4.4). Its use is prohibited at all times, as USADA also points out. Controlled data from the MOTS-MET study (NCT07505745) are not expected until 2027/2028. Until then, MOTS-c remains an experimental peptide.